Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Endocyte, Inc. (ECYT - Snapshot Report) reported fourth quarter 2012 net loss per share of 2 cents, in line with the Zacks Consensus Estimate and narrower than  the year-ago loss of 30 cents.

Fourth quarter 2012 revenues were $14.5 million compared with $0.2 million in 2011. Revenues comprised solely of collaboration revenues. Revenues in the final quarter of 2012 edged past the Zacks Consensus Estimate of $14 million.

In the fourth quarter of 2012, research and development expenses were $10.5 million, up 35.7%. The company’s effort to develop its pipeline was primarily responsible for the increase. In the fourth quarter of 2012, general and administrative (G&A) expenses jumped 73% to $4.95 million. The increase was attributable to establishing commercial capability. An increase in compensation expenses was also responsible for pushing G&A costs up.

Full year 2012 net loss per share was 48 cents compared with a loss of $1.40 per share in 2011. The Zacks Consensus Estimate for 2012 hinted at a net loss of 47 cents per share. Revenues in 2012 were $34.7 million compared with 0.2 million in 2011. Revenues for 2012 surpassed the Zacks Consensus Estimate of $34 million.

In 2012, the company submitted a marketing authorization application (MAA) for its oncology candidate, vintafolide (MK-8109/EC145) in the EU. Endocyte is also looking for EU approval of etarfolatide (EC20) along with vintafolide. Etarfolatide is developed for the identification of tumors that overexpress folate receptors and that may respond to folate-targeted therapy. Both the candidates were granted orphan drug status in the EU in 2012. The company expects a decision from the European Commission on both the candidates towards the end of 2013.

Endocyte and its partner, Merck & Co. Inc. (MRK - Analyst Report), are looking to get vintafolide approved as a treatment of patients suffering from folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). They entered into a partnership in Apr 2012.

Under this agreement, Endocyte granted Merck an exclusive license to develop, manufacture and commercialize the candidate.

2013 Guidance

Total expenses, net of Merck reimbursements, are expected around $65 million in 2013.

Cash, cash equivalents and investments are expected in the range of $145 - $160 million as on Dec 31, 2013.

Endocyte carries a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. (LCI - Snapshot Report) and United Therapeutics Corporation (UTHR - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%